GenI-AIRSPACE Trial

Genetic testing is transforming prostate cancer care. It plays a crucial role in disease management and prevention. Understanding genetic predispositions empowers us to make informed decisions about our health.

The GenI-AIRSPACE trial explores how genomic insights can refine treatment decisions for patients with favourable intermediate-risk (FIR) prostate cancer. This helps safely delay unnecessary interventions or identify those needing timely treatment. By participating, patients will gain access to our advanced genomic tests through optimising care while reducing unwanted treatments.

Our Goal

The trial will use genomic testing to identify patients with a lower risk of disease progression at the time of diagnosis, hence allowing for less invasive care.

Our goal is to enhance the prediction of 10-year patient outcomes by developing and demonstrating the superiority of genomically informed screening assays in the context of a world-first, randomised clinical trial in patients with FIR prostate cancer.

The Genomic Tests

We will apply three genomic tests to stratify patients’ risks of progression, including a germline and somatic tumour screening panel, as well as the Decipher transcriptional assay.

DNA Damage Response Gene+ panel assay We have designed a capture panel that encompasses all major prostate cancer-associated germline loci. This panel includes, all candidate DNA Damage Response genes, Genome Wide Association Study loci and all interacting germline-somatic hits identified from our studies. We will perform targeted sequencing for this panel to 120x coverage on an illumina Novo-Seq using the UMCCR Genomics Core at the VCCC. There are three genes of interest: BRAC1/BRAC2 and ATM.
illumina TruSight Oncology 500 The TruSight™ Oncology 500 (TSO500) is a pan-cancer next generating sequencing assay covering 523 cancer-relevant genes that enables determination of DNA somatic variants.
We will employ the Decipher expression test (Veracyte, San Francisco, CA USA) on these original biopsy cores as an additional stratification tool for comparison with an FDA approved genomic stratification test.